5月19日,康宁杰瑞制药-B股价午前上涨5.37%,报7.06港元。公司与石药集团合作开发的KN026在HER2阳性胃癌治疗的II/III期临床试验中达到无进展生存期(PFS)主要终点。独立数据监察委员会审查结果显示,KN026联合化疗显著改善患者PFS,并降低疾病进展或死亡风险,具有统计学显著性和临床意义。详细数据将在国际学术会议上公布。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.